FDA-cleared profile

Data Analysis Facilitation Suite (DAFS)

Voronoi Health Analytics Incorporated · CT/CTA · FDA-cleared (510(k))

Authorized purpose: DAFS automatically segments anatomy on DICOM Part 10 CT images and supports reviewed two- and three-dimensional visualization, editing, and area, volume, and intensity measurements; it does not provide diagnostic interpretation.

Clinical role
Adjunct CT segmentation, vertebral labeling, visualization, measurement, editing, and reporting.
Images and patients
CT/CTA · Multi-region
Key limitation
Keep in mind: DAFS is intended for use as an adjunct to clinical assessment. The device does not provide diagnostic interpretation, and all results must be reviewed and confirmed by a qualified healthcare professional.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: DAFS automatically segments anatomy on DICOM Part 10 CT images and supports reviewed two- and three-dimensional visualization, editing, and area, volume, and intensity measurements; it does not provide diagnostic interpretation.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Multi-region Input: DICOM Part 10 CT image studies.
  • Who uses it?Intended users: Trained healthcare professionals who review and edit radiological image-processing outputs.
  • What does the software produce?Output: Editable anatomical segmentations, vertebral landmarks, 2D/3D visualizations, measurements, and tabular or graphical reports.
  • What is its most important limitation?Key limitation: DAFS is intended for use as an adjunct to clinical assessment. The device does not provide diagnostic interpretation, and all results must be reviewed and confirmed by a qualified healthcare professional.

Clinical takeaway. Clinical role: DAFS automatically segments anatomy on DICOM Part 10 CT images and supports reviewed two- and three-dimensional visualization, editing, and area, volume, and intensity measurements; it does not provide diagnostic interpretation.

Evidence takeaway. Evidence from the reviewed source record: Exact-submission internal testing used 124 adult TCIA CT studies from multiple institutions and more than ten scanner models. Median vertebral slice error was zero and most major structures had mean Dice above 0.90; all outputs require professional review.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
DAFS automatically segments anatomy on DICOM Part 10 CT images and supports reviewed two- and three-dimensional visualization, editing, and area, volume, and intensity measurements; it does not provide diagnostic interpretation.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Adjunct CT segmentation, vertebral labeling, visualization, measurement, editing, and reporting.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
DICOM Part 10 CT image studies.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
Editable anatomical segmentations, vertebral landmarks, 2D/3D visualizations, measurements, and tabular or graphical reports.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Clinical image-processing and review environments using CT data.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Trained healthcare professionals who review and edit radiological image-processing outputs.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
DAFS is intended for use as an adjunct to clinical assessment. The device does not provide diagnostic interpretation, and all results must be reviewed and confirmed by a qualified healthcare professional.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication states the adjunct, non-diagnostic, and qualified-professional review boundaries.

Evidence summary
Exact-submission internal testing used 124 adult TCIA CT studies from multiple institutions and more than ten scanner models. Median vertebral slice error was zero and most major structures had mean Dice above 0.90; all outputs require professional review.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Exact-submission internal testing used 124 adult TCIA CT studies from multiple institutions and more than ten scanner models. Median vertebral slice error was zero and most major structures had mean Dice above 0.90; all outputs require professional review.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

Independent validation subjects

124 subjects

  • EndpointCT studies excluded from model training
  • PopulationData Analysis Facilitation Suite (DAFS)
  • Tested versionDAFS cleared in K253944

Vertebral median slice error

0 slices

  • EndpointAutomated versus reference vertebral landmarks
  • PopulationData Analysis Facilitation Suite (DAFS)
  • Tested versionDAFS cleared in K253944

Major-structure mean Dice reference

0.9 DSC

  • EndpointMost major structures exceeded this reported value
  • PopulationData Analysis Facilitation Suite (DAFS)
  • Tested versionDAFS cleared in K253944

K253944 FDA performance package for Data Analysis Facilitation Suite (DAFS)

  • DesignManufacturer independent internal validation against expert-reviewed manual reference standards
  • Population124 adult CT studies, 60 female and 64 male, from multi-institutional TCIA datasets with contrast and noncontrast scans
  • Scopeexact submission
  • Tested versionDAFS cleared in K253944
  • Samplen=124
  • IndependenceSponsor or vendor study

K253944

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K253944 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM Part 10 CT image studies.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K253944: Data Analysis Facilitation Suite (DAFS)

  2. Routing

    Source context, not route validation: DICOM Part 10 CT input with CSV, tabular, PDF, and graphical output functions described in the FDA summary; validate routing and identifier handling.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K253944: Data Analysis Facilitation Suite (DAFS) · DAFS product-family overview

  3. AI processing

    Source context, not route validation: Software application on compatible computing infrastructure. Current DAFS Node materials may inform evaluation but are not exact K253944 deployment evidence.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K253944: Data Analysis Facilitation Suite (DAFS) · DAFS product-family overview

  4. Returned objects

    Source context, not route validation: Editable anatomical segmentations, vertebral landmarks, 2D/3D visualizations, measurements, and tabular or graphical reports.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K253944: Data Analysis Facilitation Suite (DAFS)

  5. Viewer/worklist/report

    Unresolved route: Editable anatomical segmentations, vertebral landmarks, 2D/3D visualizations, measurements, and tabular or graphical reports.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K253944: Data Analysis Facilitation Suite (DAFS)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Software application on compatible computing infrastructure. Current DAFS Node materials may inform evaluation but are not exact K253944 deployment evidence.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
DICOM Part 10 CT input with CSV, tabular, PDF, and graphical output functions described in the FDA summary; validate routing and identifier handling.
  • Exact FDA submission
  • Checked 2026-09-03
Training
Only trained healthcare professionals who review and edit radiological image-processing outputs. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: DAFS is an adjunct and does not provide diagnostic interpretation. K253944 is CT-only; current vendor PET or MR product-family features must not be attributed to this clearance.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K253944 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

DICOM Part 10 CT input with CSV, tabular, PDF, and graphical output functions described in the FDA summary; validate routing and identifier handling.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. DAFS is an adjunct and does not provide diagnostic interpretation. K253944 is CT-only; current vendor PET or MR product-family features must not be attributed to this clearance.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: DAFS is an adjunct and does not provide diagnostic interpretation. K253944 is CT-only; current vendor PET or MR product-family features must not be attributed to this clearance.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K253944
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication identifies computed tomography (CT) images; it does not identify CTA, PET, or MR for this submission. Controlled directory display reconciled from exact FDA wording: computed tomography (CT) images -> CT/CTA.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-03-16
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
11Source classes checked
10Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 10 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 10 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-03 - Exact FDA submission

    Public materials reviewed for this batch do not establish the complete security posture for the exact release. Request data-flow, identity, audit, encryption, retention, support-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA K253944: Data Analysis Facilitation Suite (DAFS)

    U.S. Food and Drug Administration - Published 2026-03-16 - Accessed 2026-09-19

    Scope: purpose, anatomy, intendedUsers, input, output, evidenceSummary, modality, limitations, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. DAFS product-family overview

    Voronoi Health Analytics - Accessed 2026-09-03

    Scope: productFamily, workflowRole, deployment, implementationCapabilities, currentCommercialContext

Research history

  1. K253944 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K223556

DeepCatch

MEDICALIP Co., Ltd

DeepCatch analyzes whole-body CT images to segment skin, bone, muscle, visceral fat, subcutaneous fat, internal organs, and central nervous system structures, then calculates volumes, proportions, and three-dimensional models for physician confirmation.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2023-06-16
FDA-cleared K253649

Spectral CT Verida Family

Philips Medical Systems Technologies, Ltd.

Authorized purpose: Spectral CT Verida Family supports the labeled spectral CT acquisition, reconstruction, material-map, and professional-interpretation workflow; exact models, protocols, and derived outputs remain submission-specific.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K252992

CT Rembra RT; CT Areta RT; CT Rembra

Philips Healthcare (Suzhou) Co., Ltd.

Authorized purpose: CT Rembra RT, CT Areta RT, and CT Rembra support whole-body diagnostic imaging, oncology, radiotherapy planning, interventional, vascular, neurological, cardiovascular, and qualified lung-screening workflows for all ages.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-23
FDA-cleared K253574

SOMATOM X.cite; SOMATOM X.ceed

Siemens Medical Solutions USA, Inc.

Authorized purpose: SOMATOM X.cite and X.ceed with syngo CT VB20 support diagnostic CT, interventions, treatment preparation, radiation-therapy planning, and qualified low-dose lung screening.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-20

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history